Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean 2019 10 0?
Displaying drugs 1426 - 1450 of 3455 in total

Cabozantinib

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal...
Approved
Investigational
Matched Description: … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. …

Dabigatran etexilate

Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects...
Approved
Matched Products: … PRADAXA 75 MG SERT KAPSUL, 10 ADET ... PRADAXA 110 MG SERT KAPSUL, 10 ADET …

Pucotenlimab

Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. It is being investigated in other cancers.
Approved
Investigational

Indapamide

The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced...
Approved
Matched Mixtures name: … Triplixam 10 mg/2,5 mg/10 mg Filmtabletten ... COVERATRIX® 10 MG. / 2.5 MG. / 10 MG ... ./10 มก. …

Eltrombopag

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of...
Approved
Matched Description: … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood …

Technetium Tc-99m tilmanocept

Technetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging. It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa...
Approved
Investigational
Matched Description: … multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 …

Midostaurin

Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was...
Approved
Investigational
Matched Iupac: … 8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-4-yl ... N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{ …

Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly...
Approved
Investigational
Matched Description: … Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. …

Pentazocine

The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Approved
Vet approved
Matched Iupac: … 1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-4-ol …

Catumaxomab

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in...
Approved
Investigational
Withdrawn
Matched Description: … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. …

Iopodic acid

Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a...
Approved
Investigational
Withdrawn

Bisoctrizole

Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M . It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays. Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts...
Approved
Matched Description: … UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of 10% …

Sotatercept

Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Approved

Titanium dioxide

Titanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium. It is used as a pigment under the names titanium white, Pigment White 6 (PW6), or CI 77891. It is typically extracted from ilmenite, rutile and anatase.
Approved
Matched Mixtures name: … Koh Gen Do Aqua Foundation PK-0 ... Premium BB Cream UVA/UVB SPF36 0 Pale ... Laboratoire Remede Translucent Uv Coat Tint 0 …
Matched Products: … SPF 10 ... Adaptive Fps 10 ... Ideal Balance SPF 10 …

Betamethasone

Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Approved
Vet approved
Matched Products: … XORSONE 1:10 Cream …

Octinoxate

Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often combined with nanoparticles or other water-resistant liposomes in formulations to increase...
Approved
Investigational
Matched Mixtures name: … Premium BB Cream UVA/UVB SPF36 0 Pale ... Laboratoire Remede Translucent Uv Coat Tint 0 ... Givenchy Photo Perfexion Fluid Foundation SPF 20 Perfect Linen Tint 0 …
Matched Products: … True Illusion SPF 10 ... Finish Bronzer SPF 10 ... Quo Minimal Makeup SPF-10 …

Riociguat

Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension)...
Approved

Tetrabenazine

A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Approved
Investigational

Butenafine

Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Approved
Matched Products: … BUTAFLY % 1 LOSYON ,10 ML …

Mebeverine

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.
Approved
Investigational
Matched Products: … DUSPATALIN LIKIT 10 MG/ML, 250 ML …

Iodipamide

Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Approved
Matched Salts cas: … 2618-26-0 …

Thiamine

Thiamine or thiamin, also known as vitamin B1, is a colorless compound with the chemical formula C12H17N4OS. It is soluble in water and insoluble in alcohol. Thiamine decomposes if heated. Thiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi. Thiamine plays...
Approved
Investigational
Nutraceutical
Vet approved
Matched Mixtures name: … PreQue 10 ... PreQue 10 ... Maxi 10 Tab …
Matched Products: … BEVIGEN 2 ML AMPUL, 10 ADET ... /ML)EN FRASCOAMPOLLA POR 10 ML …

Iopamidol

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Approved
Matched Products: … IOPAMIRO 370 INJECTION 7.55 g/10 ml ... IOPAMIRO 300 INJECTION 6.12 g/10 ml …

Cefepime

Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated...
Approved
Investigational
Matched Products: … ROXIPIME 2 G IV ENJEKSIYON VE INFÜZYON IÇIN TOZ IÇEREN FLAKON ,10 ADET …
Displaying drugs 1426 - 1450 of 3455 in total